Diagnosis & Differentiation
Prospective Analysis of Mesotheliomas in Subjects with BAP1 Cancer Syndrome: Clinical Characteristics and Epigenetic Correlates of Disease
Journal of Thoracic Oncology 2025 August 5 [Link] Xinwei Wu, Frank-Villa Hernandez, Haitao Wang, Ruihong Wang, Stephanie Shiffka, Niharika Shah, Shamus R Carr, Chuong D Hoang, Andrew M Blakely, Alexandra Lebensohn, Keerti Mihsra, Sichuan Xi, Mary R Zhang, Tuana Tolunay, Sudheer Gara, Amanda Absher, Deneise Francis, Amanda Rowland, Maureen Connolly, Stephanie Jacobs, Sandra Orfgen, Kevin…
Read MoreSerum mesothelin as a response biomarker in pleural mesothelioma
Lung Cancer 2025 August [Link] Geraldine A Lynch, Jenny Symonds, Anna Morley, Emeka Azubuike-Dyer, Will Cooper, Anthony Edey, Duneesha De Fonseka, Selina Tsim Kevin Blyth Paul White, Nick A Maskell 5, Anna Bibby Abstract Background: CT scans are the current gold standard for disease monitoring for Pleural mesothelioma (PM), with radiology reported using the modified…
Read MoreSerum mesothelin as a response biomarker in pleural mesothelioma
Lung Cancer 2025 August [Link] Geraldine A Lynch, Jenny Symonds, Anna Morley, Emeka Azubuike-Dyer, Will Cooper, Anthony Edey, Duneesha De Fonseka, Selina Tsim, Kevin Blyth, Paul White, Nick A Maskell, Anna Bibby Abstract Background: CT scans are the current gold standard for disease monitoring for Pleural mesothelioma (PM), with radiology reported using the modified RECIST…
Read MoreMedical Thoracoscopy in Malignant Pleural Effusion
Cureus 2025 June 10 [Link] Amit K Rath, Sudarsan Pothal, Pallavi Bharadwaj Abstract Introduction: Malignant pleural effusion (MPE) is a common complication of advanced malignancies, often resulting in significant morbidity and impaired quality of life. In most cases, pleural fluid cytology remains negative. In the era of targeted cancer therapy, pathologists expect larger tissue samples.…
Read MorePrognostic Value of the HALP Score in Metastatic Mesothelioma: A Retrospective Study
Oncology 2025 July 8 [Link] Ozlem Dogan, Yakup Duzkopru, Tulay Eren Abstract Background: Malignant mesothelioma is a rare but aggressive cancer with limited treatment options and poor prognosis. Hemoglobin, Albumin, Lymphocyte, Platelet(HALP) score , reflecting inflammation and nutritional status, is a potential prognostic marker in various cancers. Our study aims to investigate the prognostic value…
Read MoreImmune Composition and Immunotherapy Outcomes of Mesothelioma with BAP1, CDKN2A, MTAP, and NF2 Alterations
Journal of Thoracic Oncology 2025 June 25 [Link] Ibiayi Dagogo-Jack, Owen Mitchell, Elizabeth Codd, Annie Li, Dawn Mitchell, Samantha E Flynn, Nanna Sivamanoharan, Patrick Reeves, Mark Poznansky, Ivan Valiev, Artem Kosmin, Beow Y Yeap, Grace Hambelton, A John Iafrate, Jochen K Lennerz, Yin P Hung, Hedy Kindler Abstract Background: First-line mesothelioma treatment paradigms prioritize histology…
Read MoreHMGB1 as a Key Mediator in Malignant Mesothelioma and a Potential Target for Asbestos-Related Cancer Therapy
Toxics 2025 May 28 [Link] Yi-Fang Zhong, Chan Ding, Chun-Ji Yao, Jia-Chun Wang, Min-Qian Feng, Xiao-Xue Gong, Lin Yu, Hua-Dong Xu, Hai-Ling Xia Abstract Malignant mesothelioma (MM) is a highly aggressive cancer strongly associated with asbestos exposure, and accumulating evidence suggests that high mobility group box 1 (HMGB1) plays a central role in its pathogenesis.…
Read MoreLoss of MTAP expression is not an accurate surrogate for CDKN2A homozygous deletions in peritoneal mesothelioma
Histopathology 2025 June 25 [Link] Andrea Quaranta, Andrea Marzullo, Francesco Fortarezza, Sonia Maniglio, Concetta Caporusso, Floriana Pentimone, Federica Pezzuto, Domenica Cavone, Teresa Lettini, Mario Magistro, Cecilia Salzillo, Luigi Vimercati, Paolo Graziano, Gabriella Serio, Antonio d’Amati Abstract Aims: Mesothelioma is a malignant neoplasm of the serosal membranes originating from mesothelial cells. Peritoneal mesothelioma is the second…
Read More8C7: A Fully Human Anti-PTGFRN Monoclonal Antibody-Drug Conjugate Inhibiting Tumour Growth of Mesothelioma and Paediatric Medulloblastoma Cell Lines
Journal of Cellular and Molecular Medicine 2025 June [Link] Jorge Marquez, Jianping Dong, Binbin Yue, Jun Hayashi, Chun Dong, Mitsuo Oshimura, Ginette Serrero Abstract Antibody Drug Conjugates (ADCs) are attractive for developing cancer-targeted therapies, particularly for cancers with unmet needs. Identification of a druggable internalising cell-surface target enables the development of internalising monoclonal antibodies to…
Read MorePBK Expression Promotes the Aggressive Phenotypes of Mesothelioma
Cancer Science 2025 June 24 [Link] Kazumi Hori, Ichidai Tanaka, Tatsuhiro Sato, Mika Sato, Yuta Kodama, Hideyuki Itoigawa, Yuichi Abe, Taketo Kato, Ayumu Taguchi, Mitsuo Sato, Yoshitaka Sekido, Toyofumi Fengshi Chen-Yoshikawa, Makoto Ishii Abstract Mesothelioma is one of the most aggressive neoplasms worldwide that has a particularly poor prognosis. We have previously discovered that oxytocin…
Read More
Skip to content